News and Announcements
4Dx Series B Capital Raise Round Now Open to Investors
- Published October 10, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Series B capital raising round is open to sophisticated, professional and overseas investors
- Funds from this round will be used to continue studies
- The investment round is scheduled to close the earlier of 1 March 2018
4Dx is pleased to announce to our extended network that our Series B capital raising round is open to sophisticated, professional and overseas investors. This will be followed by a retail fundraising round component open to the general investment community in the coming weeks.
For those interested in an updated investment snapshot, you may download our 4Dx Company Information Deck: Series B Capital Raising October 2017 on our 4Dx Investor webpage.
For those sophisticated, professional and overseas investors wishing to register your interest, please do so via the Register Your Interest webform on our 4Dx Investor webpage. You will be contacted with further information on how to access the Information Memorandum and other investment documentation contained in our private Series B Data Room.
For those interested in participating in our retail fundraising round, you will receive notification of how to participate in coming weeks.
Funds from this round will be used to continue studies to validate the accuracy and repeatability of software product, make FDA submissions for our core software, expand our US office, with a focus on building market opportunity in that geography, and provide working capital to meet ongoing operational costs.
The investment round is scheduled to close the earlier of 1 March 2018, or once our A$4,995,000 target is achieved.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
